Latest On ARCA biopharma, Inc (ABIO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-25 02:30 EST | News | ARCA biopharma GAAP EPS of -$0.09 | N/A |  |
| 2022-10-29 02:46 EST | News | ARCA biopharma GAAP EPS of -$0.16 | N/A | |
| 2022-08-03 02:31 EST | News | ARCA biopharma GAAP EPS of -$0.22 | N/A | |
| 2022-05-04 02:46 EST | News | ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play | N/A | |
| 2022-05-03 08:46 EST | News | ARCA biopharma GAAP EPS of -$0.23 | N/A | |
| 2022-04-19 02:15 EST | News | ARCA biopharma establishes special board committee to evaluate strategic options | N/A | |
| 2022-04-01 02:01 EST | News | Arca biopharma fails to meet key goal in mid-stage trial for COVID-19 therapy | N/A | |
| 2022-03-14 23:00 EST | News | ARCA biopharma GAAP EPS of -$1.39 | N/A | |
| 2021-12-02 12:16 EST | News | ARCA Bio completes enrollment in mid-stage rNAPc2 trail in COVID-19 | N/A | |
| 2021-10-29 13:17 EST | News | ARCA biopharma shares surge 30% on positive DSMC recommendation for rNAPc2 COVID-19 trial | N/A | |
| 2021-09-16 14:02 EST | News | ARCA Biopharma enrolls first international patient in mid-stage COVID-19 trial | N/A | |
| 2021-08-23 22:32 EST | News | ARCA biopharma (ABIO) Investor Presentation - Slideshow | N/A | |
| 2021-08-09 22:18 EST | News | ARCA Biopharma submits PCT patent application for rNAPc2 in COVID-19 | N/A | |
| 2021-08-04 22:46 EST | News | ARCA biopharma reports Q2 results | N/A | |
| 2021-07-20 17:31 EST | News | ARCA Bio inks rNAPc2 COVID-19 patent assignment deal | N/A | |
| 2021-07-20 17:27 EST | News | ARCA Bio updates on mid-stage rNAPc2 study in COVID-19, shares down 9% | N/A | |
| 2021-05-03 17:00 EST | News | ARCA Biopharma names Jeff Dekker as chief financial officer | N/A | |
| 2021-03-19 10:47 EST | News | ARCA biopharma reports FY results | N/A | |
| 2020-12-16 01:18 EST | News | Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19 | N/A | |
| 2020-11-25 11:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 12:35 EST | News | ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment | N/A | |
| 2020-11-07 15:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 03:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-04 07:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 17:25 EST | News | ARCA biopharma reports Q3 results | N/A | |
| 2020-11-01 15:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-07 09:01 EST | News | ARCA biopharma on go with mid-stage study for AB201 in COVID-19 | N/A | |
| 2020-09-25 16:45 EST | Insider Trade | ROBERT E CONWAY has directly acquired 5,000 shares and currently holds 20,000 shares. | Buy | |
| 2020-09-24 16:30 EST | Insider Trade | ROBERT E CONWAY has directly acquired 3,056 shares and currently holds 15,000 shares. | Buy | |
| 2020-09-21 17:15 EST | Insider Trade | ROBERT E CONWAY has directly acquired 10,000 shares and currently holds 11,944 shares. | Buy | |
| 2020-09-21 12:48 EST | News | ARCA biopharma files to commence AB201 study for COVID-19 | N/A | |
| 2020-08-13 10:05 EST | News | ARCA biopharma readies mid-stage study of AB201 in COVID-19 | N/A | |
| 2020-08-08 00:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 09:04 EST | News | ARCA biopharma EPS beats by $1.85 | N/A | |
| 2020-07-23 16:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-15 06:02 EST | News | Arca biopharma ups stock sales agreement with JonesTrading | N/A | |
| 2020-06-02 04:00 EST | Earnings Estimate | An EPS average of -$2.51 is estimated for the quarter ending on September 30, 2020. | Sell | |
| 2020-06-01 17:54 EST | News | ARCA bio plummets 20% on $9.4M direct offering | N/A | |
| 2020-05-28 09:43 EST | News | ARCA Bio launches AB201 program in COVID-19 | N/A | |
| 2020-05-10 00:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-09 22:17 EST | News | Mixed shelf filings rise as companies prepare to raise capital | N/A | |
| 2020-05-07 07:05 EST | News | ARCA biopharma EPS beats by $1.21 | N/A | |
| 2020-04-10 16:00 EST | News | ARCA biopharma EPS beats by $0.27 | N/A | |
| 2020-04-09 08:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 15:19 EST | Earnings Estimate | An EPS average of -$8.80 is estimated for the 2021 year. | Sell | |
| 2020-02-27 15:19 EST | Analyst Rating | The Analyst Target Price has decreased from $7.5 to $7. | Neutral | |
| 2020-02-21 23:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-20 11:15 EST | Earnings | Earnings have been released on February 26, 2009, with -$103,560.84 earnings per share. | Buy | |
| 2020-02-20 11:15 EST | Earnings | Earnings have been released on October 31, 2008, with -$128,853.04 earnings per share. | Buy | |
| 2020-01-21 19:00 EST | Earnings | Earnings have been released on November 6, 2019, with -$0.76 earnings per share. | Buy | |
About ARCA biopharma, Inc (ABIO):
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
General
- Name ARCA biopharma, Inc
- Symbol ABIO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 13
- Last Split Factor1:18
- Last Split Date2019-04-04
- Fiscal Year EndDecember
- IPO Date1997-08-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://arcabio.com
View More
Valuation
- Price/Book (Most Recent Quarter) 0.77
- Enterprise Value EBITDA 2.16
View More
Financials
- Most Recent Quarter 2020-09-30
- Return on Assets -12%
- Return on Equity -20%
- Earnings Per Share -$6.67
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 37.85 million
- EBITDA -6456000
- Analyst Target Price $7
- Book Value Per Share $5.43
View More
Share Statistics
- Shares Outstanding 9.32 million
- Shares Float 9.28 million
- % Held by Insiders 40%
- % Held by Institutions 8.43%
- Shares Short 197614
- Shares Short Prior Month 119719
- Short Ratio 0.13
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 2.77
- 52 Week High $10.25
- 52 Week Low $2.51
- 50 Day Moving Average 4.51
- 200 Day Moving Average 4.36
View More
Dividends
- Dividend Date 2019-04-04
- ExDividend Date N/A
- Dividend Yield 0%
View More
ARCA biopharma, Inc (ABIO) Dividend Calendar:
ABIO's last dividend payment was made to shareholders on April 4, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
ARCA biopharma, Inc (ABIO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-02 | $N/A | -$0.33 | ||
| 2020-06-30 | 2020-08-05 | $N/A | -$0.73 | -$2.58 | 71.71% |
| 2020-03-31 | 2020-05-06 | $N/A | -$0.83 | -$2.04 | 59.31% |
| 2019-12-31 | 2020-02-18 | $N/A | -$0.69 | -$0.99 | 30.3% |
| 2019-09-30 | 2019-11-06 | $N/A | -$0.76 | -$1.30 | 41.54% |
| 2019-06-30 | 2019-08-01 | $N/A | -$1.14 | -$1.86 | 38.71% |
| 2019-03-31 | 2019-05-08 | $N/A | -$1.86 | -$1.98 | 6.06% |
| 2018-12-31 | 2019-02-27 | $N/A | -$1.80 | -$2.52 | 28.57% |
| 2018-09-30 | 2018-11-14 | $N/A | -$1.98 | -$3.42 | 42.11% |
| 2018-06-30 | 2018-08-09 | $N/A | -$2.70 | -$3.96 | 31.82% |
| 2018-03-31 | 2018-05-08 | $N/A | -$3.60 | -$3.60 | 0% |
| 2017-12-31 | 2018-03-22 | $N/A | -$6.12 | -$9.36 | 34.62% |
| 2017-09-30 | 2017-11-09 | $N/A | -$7.02 | ||
| 2017-06-30 | 2017-08-03 | $N/A | -$10.66 | ||
| 2017-03-31 | 2017-05-15 | $N/A | -$8.59 | ||
| 2016-12-31 | 2017-03-21 | $N/A | -$8.41 | ||
| 2016-09-30 | 2016-11-14 | $N/A | -$9.25 | ||
| 2016-06-30 | 2016-08-09 | $N/A | -$7.73 | ||
| 2016-03-31 | 2016-05-11 | $N/A | -$7.25 | ||
| 2015-12-31 | 2016-03-17 | $N/A | -$6.30 | ||
| 2015-09-30 | 2015-11-13 | $N/A | -$5.61 | ||
| 2015-06-30 | 2015-08-12 | $N/A | -$12.38 | ||
| 2015-03-31 | 2015-05-13 | $N/A | -$16.33 | ||
| 2014-12-31 | 2015-03-20 | $N/A | -$15.55 | ||
| 2014-09-30 | 2014-11-13 | $N/A | -$13.69 | ||
| 2014-06-30 | 2014-08-14 | $N/A | -$14.42 | ||
| 2014-03-31 | 2014-05-14 | $N/A | -$16.02 | ||
| 2013-12-31 | 2014-03-21 | $N/A | -$23.66 | ||
| 2013-09-30 | 2013-11-13 | $N/A | -$20.04 | ||
| 2013-06-30 | 2013-08-14 | $N/A | -$82.19 | ||
| 2013-03-31 | 2013-05-14 | $N/A | -$44.47 | ||
| 2012-12-31 | 2013-02-28 | $N/A | -$47.60 | ||
| 2012-09-30 | 2012-11-02 | $N/A | -$51.15 | ||
| 2012-06-30 | 2012-08-07 | $N/A | -$71.21 | ||
| 2012-03-31 | 2012-05-08 | $N/A | -$87.43 | ||
| 2011-12-31 | 2012-03-01 | $N/A | -$122.76 | ||
| 2011-09-30 | 2011-10-28 | $N/A | -$131.19 | ||
| 2011-06-30 | 2011-08-09 | $N/A | $21.68 | ||
| 2011-03-31 | 2011-05-10 | $N/A | -$188.77 | ||
| 2010-12-31 | 2011-03-03 | $N/A | -$141.76 | ||
| 2010-09-30 | 2010-10-29 | $N/A | -$180.56 | ||
| 2010-06-30 | 2010-08-10 | $N/A | -$196.51 | ||
| 2010-03-31 | 2010-05-11 | $N/A | -$242.32 | ||
| 2009-12-31 | 2010-02-25 | $N/A | -$659.39 | ||
| 2009-09-30 | 2009-10-30 | $N/A | -$429.88 | ||
| 2009-06-30 | 2009-08-11 | $N/A | -$858.09 | ||
| 2009-03-31 | 2009-05-08 | $N/A | $965.51 | ||
| 2008-12-31 | 2009-02-26 | $15.25 million | -$103,560.84 | ||
| 2008-09-30 | 2008-10-30 | $N/A | -$2,419.20 | -$2,872.80 | 15.79% |
| 2008-06-30 | 2008-07-23 | $N/A | -$82,015.77 | -$2,721.60 | -2913.51% |
| 2008-03-31 | 2008-05-08 | $N/A | -$5,140.80 | -$4,536.00 | -13.33% |
| 2007-12-31 | 2008-02-27 | $46.86 million | -$3,326.40 | -$4,006.80 | 16.98% |
| 2007-09-30 | 2007-11-01 | $N/A | -$4,082.40 | -$3,723.30 | -9.64% |
| 2007-06-30 | 2007-08-01 | $N/A | $8,164.80 | -$4,300.80 | 289.84% |
| 2007-03-31 | 2007-05-09 | $N/A | -$4,384.80 | -$4,460.40 | 1.69% |
| 2006-12-31 | 2007-02-27 | -$6,199.20 | -$6,598.80 | 6.06% | |
| 2006-09-30 | 2006-11-02 | -$7,711.20 | -$5,670.00 | -36% | |
| 2006-06-30 | 2006-08-03 | -$5,443.20 | -$5,644.80 | 3.57% | |
| 2006-03-31 | 2006-05-05 | -$6,048.00 | -$4,418.40 | -36.88% | |
| 2005-12-31 | 2006-02-27 | -$7,408.80 | -$7,063.20 | -4.89% | |
| 2005-09-30 | 2005-11-01 | -$6,652.80 | -$6,559.75 | -1.42% | |
| 2005-06-30 | 2005-08-04 | -$6,048.00 | -$6,615.00 | 8.57% | |
| 2005-03-31 | 2005-05-02 | -$5,896.80 | -$6,091.20 | 3.19% | |
| 2004-12-31 | 2005-02-15 | -$6,048.00 | -$9,256.80 | 34.66% | |
| 2004-09-30 | 2004-11-09 | -$5,140.80 | -$4,968.00 | -3.48% | |
| 2004-06-30 | 2004-08-09 | -$5,140.80 | -$5,473.44 | 6.08% | |
| 2004-03-31 | 2004-05-06 | -$9,828.00 | -$5,292.00 | -85.71% | |
| 2003-12-31 | 2004-02-05 | -$5,443.20 | -$5,216.40 | -4.35% | |
| 2003-09-30 | 2003-10-30 | -$7,711.20 | -$4,989.60 | -54.55% | |
| 2003-06-30 | 2003-07-31 | -$8,164.80 | -$9,979.20 | 18.18% | |
| 2003-03-31 | 2003-05-01 | -$12,410.53 | |||
| 2002-09-30 | 2002-10-24 | -$2,876.42 | |||
| 2002-06-30 | 2002-07-25 | -$16,590.15 | |||
| 2002-03-31 | 2002-04-25 | -$45,913.37 | |||
| 2001-12-31 | 2002-02-06 | -$27,664.40 | |||
| 2001-09-30 | 2001-10-25 | -$26,839.19 | |||
| 2001-06-30 | 2001-06-30 | -$24,866.74 | |||
| 2001-03-31 | 2001-03-31 | -$22,046.91 | |||
| 2000-12-31 | 2000-12-31 | -$22,222.22 | |||
| 2000-09-30 | 2000-10-26 | -$13,608.00 | -$17,236.80 | 21.05% | |
| 1999-12-31 | 2000-02-03 | -$17,690.40 | -$18,597.60 | 4.88% | |
| 1999-09-30 | 1999-11-02 | -$14,968.80 | -$17,236.80 | 13.16% | |
| 1998-12-31 | 1999-02-11 | -$14,968.80 | -$11,793.60 | -26.92% | |
| 1998-09-30 | 1998-10-29 | -$19,051.20 | -$11,566.80 | -64.71% | |
| 1998-06-30 | 1998-07-30 | -$14,061.60 | -$12,020.40 | -16.98% | |
| 1998-03-31 | 1998-04-30 | -$9,525.60 | -$11,793.60 | 19.23% | |
| 1997-12-31 | 1998-02-02 | -$5,443.20 | -$8,164.80 | 33.33% | |
| 1997-09-30 | 1997-10-21 | -$6,804.00 | -$5,670.00 | -20% |
ARCA biopharma, Inc (ABIO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 365000 | 384000 | N/A |
| Income Before Tax | N/A | N/A | -1.32 million | -1.24 million | N/A |
| Selling General Administrative | N/A | N/A | 975000 | 894000 | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | -1.29 million | -1.28 million | N/A |
| Operating Income | N/A | N/A | -1.34 million | -1.28 million | N/A |
| Income Tax Expense | N/A | -9000 | N/A | -16000 | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | 36000 | N/A |
| Net Income From Continuing Operations | N/A | N/A | -1.32 million | -1.23 million | N/A |
| Net Income Applicable to Common Shares | -1.99 million | -1.3 million | -1.32 million | -1.23 million | N/A |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -3000 | N/A | N/A |
| Change to Liabilities | N/A | 190000 | -293000 | 283000 | N/A |
| Total Cash Flow from Investing Activities | N/A | -3000 | -3000 | -2000 | N/A |
| Net Borrowings | N/A | -135000 | N/A | -118000 | N/A |
| Total Cash Flow from Financial Activities | 42.06 million | N/A | N/A | -122000 | N/A |
| Change to Operating Activities | N/A | 40000 | -114000 | -266000 | N/A |
| Change in Cash | 40.05 million | N/A | -1.69 million | -1.28 million | N/A |
| Total Cash from Operating Activities | -2 million | -1.04 million | -1.69 million | -1.16 million | N/A |
| Depreciation | 26000 | N/A | 25000 | 24000 | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | -514000 | N/A | -4000 | N/A |
| Change to Net Income | N/A | 4000 | 16000 | 27000 | N/A |
| Capital Expenditures | N/A | N/A | 3000 | 2000 | N/A |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 1.53 million | N/A | 1.16 million | 926000 | N/A |
| Total Stockholder Equity | 50.46 million | N/A | 6.31 million | 7.61 million | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | 51.98 million | N/A | 7.46 million | 8.54 million | N/A |
| Common Stock | N/A | 2000 | 2000 | 2000 | N/A |
| Other Current Assets | 841000 | N/A | 704000 | 117000 | N/A |
| Retained Earnings | -149.03 million | -147.04 million | -145.74 million | -144.42 million | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | 24000 | 24000 | 24000 | N/A |
| Cash | 51.1 million | N/A | 6.67 million | 8.36 million | N/A |
| Total Current Liabilities | 1.53 million | N/A | 1.16 million | 926000 | N/A |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | N/A | 36000 | 59000 | 32000 | N/A |
| Total Current Assets | 51.94 million | N/A | 7.38 million | 8.48 million | N/A |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | N/A | 10.31 million | 6.31 million | 7.61 million | N/A |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 761000 | N/A | 167000 | 418000 | N/A |
ARCA biopharma, Inc (ABIO) Chart:
ARCA biopharma, Inc (ABIO) News:
Below you will find a list of latest news for ARCA biopharma, Inc (ABIO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ARCA biopharma, Inc (ABIO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.75 | CALL | 20 | 117 | 422.09 | TRUE | -0.2 | -0.21 |
| 2024-05-17 | 5 | 0.05 | CALL | 76 | 1504 | 159.73 | FALSE | 0.02 | 0.67 |
| 2024-05-17 | 7.5 | 0.05 | CALL | 0 | 19 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.05 | PUT | 3 | 921 | 126.27 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 432.74 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 1289.55 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.8 | CALL | 20 | 129 | 54.08 | TRUE | -0.2 | -0.2 |
| 2024-06-21 | 5 | 0.2 | CALL | 12 | 47 | 131.22 | FALSE | 0.1 | 1 |
| 2024-06-21 | 7.5 | 0.1 | CALL | 0 | 8 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.1 | PUT | 0 | 270 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 1.8 | PUT | 0 | 14 | 147 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 4.1 | PUT | 0 | 2 | 311.13 | TRUE | 0 | 0 |
| 2024-09-20 | 2.5 | 1.05 | CALL | 0 | 272 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 5 | 0.2 | CALL | 38 | 27 | 76.27 | FALSE | -0.05 | -0.2 |
| 2024-09-20 | 7.5 | 0.25 | CALL | 0 | 30 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 2.5 | 0.2 | PUT | 0 | 9 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 5 | 2.4 | PUT | 0 | 10 | 223.83 | TRUE | 0 | 0 |
| 2024-09-20 | 7.5 | 0 | PUT | 0 | 0 | 210.44 | TRUE | 0 | 0 |
| 2024-12-20 | 2.5 | 1.25 | CALL | 0 | 10 | 0 | TRUE | 0 | 0 |
| 2024-12-20 | 5 | 0.35 | CALL | 0 | 15 | 332.13 | FALSE | 0 | 0 |
| 2024-12-20 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 5 | 0 | PUT | 0 | 0 | 147.65 | TRUE | 0 | 0 |
| 2024-12-20 | 7.5 | 0 | PUT | 0 | 0 | 144.66 | TRUE | 0 | 0 |
Latest ABIO Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 1:50 PM EST | 26 | $2.3 |
| Jun 13, 2022 1:50 PM EST | 74 | $2.3 |
ARCA biopharma, Inc (ABIO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000156459020031694/0001564590-20-031694-index.htm |
| 2020-05-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/907654/000000000020004302/0000000000-20-004302-index.htm |
| 2018-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000003877718000045/0000038777-18-000045-index.htm |
| 2018-03-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000003877718000149/0000038777-18-000149-index.htm |
| 2019-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000103738919000002/0001037389-19-000002-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000103738920000132/0001037389-20-000132-index.htm |
| 2018-03-05 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/907654/000107261318000184/0001072613-18-000184-index.htm |
| 2018-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000110465918008484/0001104659-18-008484-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000110465918009147/0001104659-18-009147-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000110465919007350/0001104659-19-007350-index.htm |
| 2020-01-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000110465920006493/0001104659-20-006493-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000114420418009015/0001144204-18-009015-index.htm |
| 2018-04-18 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/907654/000119312518120604/0001193125-18-120604-index.htm |
| 2018-04-18 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/907654/000119312518120614/0001193125-18-120614-index.htm |
| 2018-09-10 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/907654/000119312518270139/0001193125-18-270139-index.htm |
| 2018-09-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/907654/000119312518278722/0001193125-18-278722-index.htm |
| 2019-01-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000119312519017177/0001193125-19-017177-index.htm |
| 2019-03-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000119312519070964/0001193125-19-070964-index.htm |
| 2019-05-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000119312519143045/0001193125-19-143045-index.htm |
| 2019-05-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000119312519151798/0001193125-19-151798-index.htm |
| 2019-06-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000119312519186177/0001193125-19-186177-index.htm |
| 2020-02-26 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/907654/000119312520050219/0001193125-20-050219-index.htm |
| 2020-05-07 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/907654/000119312520136266/0001193125-20-136266-index.htm |
| 2020-05-18 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/907654/000119312520145073/0001193125-20-145073-index.htm |
| 2020-06-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000119312520159219/0001193125-20-159219-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013927/0001209191-18-013927-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013928/0001209191-18-013928-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013931/0001209191-18-013931-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013932/0001209191-18-013932-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013935/0001209191-18-013935-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013936/0001209191-18-013936-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013937/0001209191-18-013937-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013939/0001209191-18-013939-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013940/0001209191-18-013940-index.htm |
| 2018-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118013942/0001209191-18-013942-index.htm |
| 2018-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118015074/0001209191-18-015074-index.htm |
| 2018-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118015077/0001209191-18-015077-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118016685/0001209191-18-016685-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118016689/0001209191-18-016689-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118016691/0001209191-18-016691-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118016693/0001209191-18-016693-index.htm |
| 2018-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118016698/0001209191-18-016698-index.htm |
| 2018-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118023118/0001209191-18-023118-index.htm |
| 2018-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919118023122/0001209191-18-023122-index.htm |
| 2020-09-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919120051302/0001209191-20-051302-index.htm |
| 2020-09-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919120051890/0001209191-20-051890-index.htm |
| 2020-09-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000120919120052094/0001209191-20-052094-index.htm |
| 2020-06-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000138713120005573/0001387131-20-005573-index.htm |
| 2018-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/907654/000145817718000001/0001458177-18-000001-index.htm |
| 2020-06-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/907654/000153561020000096/0001535610-20-000096-index.htm |
| 2018-01-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018000237/0001564590-18-000237-index.htm |
| 2018-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018003257/0001564590-18-003257-index.htm |
| 2018-03-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018004399/0001564590-18-004399-index.htm |
| 2018-03-22 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/907654/000156459018006566/0001564590-18-006566-index.htm |
| 2018-03-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018006579/0001564590-18-006579-index.htm |
| 2018-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018008254/0001564590-18-008254-index.htm |
| 2018-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018008752/0001564590-18-008752-index.htm |
| 2018-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459018011830/0001564590-18-011830-index.htm |
| 2018-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018011864/0001564590-18-011864-index.htm |
| 2018-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018014531/0001564590-18-014531-index.htm |
| 2018-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018015077/0001564590-18-015077-index.htm |
| 2018-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018018114/0001564590-18-018114-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459018021065/0001564590-18-021065-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018021090/0001564590-18-021090-index.htm |
| 2018-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018023272/0001564590-18-023272-index.htm |
| 2018-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018024081/0001564590-18-024081-index.htm |
| 2018-10-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018024466/0001564590-18-024466-index.htm |
| 2018-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459018029560/0001564590-18-029560-index.htm |
| 2018-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018029594/0001564590-18-029594-index.htm |
| 2018-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459018031208/0001564590-18-031208-index.htm |
| 2019-01-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019001155/0001564590-19-001155-index.htm |
| 2019-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019003354/0001564590-19-003354-index.htm |
| 2019-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/907654/000156459019004882/0001564590-19-004882-index.htm |
| 2019-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019004936/0001564590-19-004936-index.htm |
| 2019-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019007204/0001564590-19-007204-index.htm |
| 2019-03-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019008641/0001564590-19-008641-index.htm |
| 2019-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019010715/0001564590-19-010715-index.htm |
| 2019-04-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019010923/0001564590-19-010923-index.htm |
| 2019-04-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019012247/0001564590-19-012247-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459019017210/0001564590-19-017210-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019017283/0001564590-19-017283-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019017999/0001564590-19-017999-index.htm |
| 2019-05-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019019829/0001564590-19-019829-index.htm |
| 2019-06-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019024070/0001564590-19-024070-index.htm |
| 2019-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459019027966/0001564590-19-027966-index.htm |
| 2019-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019028011/0001564590-19-028011-index.htm |
| 2019-10-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019036859/0001564590-19-036859-index.htm |
| 2019-10-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/907654/000156459019037938/0001564590-19-037938-index.htm |
| 2019-10-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/907654/000156459019037939/0001564590-19-037939-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019041036/0001564590-19-041036-index.htm |
| 2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459019041051/0001564590-19-041051-index.htm |
| 2019-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459019045742/0001564590-19-045742-index.htm |
| 2020-02-18 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/907654/000156459020005032/0001564590-20-005032-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020005048/0001564590-20-005048-index.htm |
| 2020-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020008703/0001564590-20-008703-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459020021946/0001564590-20-021946-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020021999/0001564590-20-021999-index.htm |
| 2020-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020027369/0001564590-20-027369-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020027745/0001564590-20-027745-index.htm |
| 2020-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020028159/0001564590-20-028159-index.htm |
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020031680/0001564590-20-031680-index.htm |
| 2020-07-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000156459020031694/0001564590-20-031694-index.htm |
| 2020-07-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020032355/0001564590-20-032355-index.htm |
| 2020-07-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000156459020032360/0001564590-20-032360-index.htm |
| 2020-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020033048/0001564590-20-033048-index.htm |
| 2020-07-22 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/907654/000156459020033060/0001564590-20-033060-index.htm |
| 2020-08-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459020036784/0001564590-20-036784-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020036857/0001564590-20-036857-index.htm |
| 2020-08-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020039733/0001564590-20-039733-index.htm |
| 2020-08-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020042033/0001564590-20-042033-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020044129/0001564590-20-044129-index.htm |
| 2020-10-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020045968/0001564590-20-045968-index.htm |
| 2020-10-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/907654/000156459020048346/0001564590-20-048346-index.htm |
| 2020-10-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/907654/000156459020048349/0001564590-20-048349-index.htm |
| 2020-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/907654/000156459020049634/0001564590-20-049634-index.htm |
| 2020-11-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/907654/000156459020049656/0001564590-20-049656-index.htm |
| 2020-05-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/907654/999999999520001219/9999999995-20-001219-index.htm |
| 2018-05-10 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/907654/999999999718005653/9999999997-18-005653-index.htm |
| 2019-05-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/907654/999999999719004572/9999999997-19-004572-index.htm |
ARCA biopharma, Inc (ABIO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ARCA biopharma, Inc (ABIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 40%Institutional Ownership: 843%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-02-26 | Anthony A. Jr. Florence | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013932/0001209191-18-013932-index.htm |
| 2018-04-02 | Brian L. Selby | VP, Finance | Sell | 1,114.00 | 0.50 | 556.33 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118023118/0001209191-18-023118-index.htm |
| 2018-02-26 | DAVID M MOTT | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013936/0001209191-18-013936-index.htm |
| 2018-02-26 | FOREST BASKETT | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013931/0001209191-18-013931-index.htm |
| 2018-02-26 | Growth Equity Opportunities IV, LLC | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013927/0001209191-18-013927-index.htm |
| 2018-02-27 | HEALTHCARE CAPITAL PARTNERS LP VENROCK | 10% Share Holder | Sell | 41,331.00 | 0.53 | 21,905.43 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000145817718000001/0001458177-18-000001-index.htm |
| 2018-02-26 | Jon Sakoda | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013937/0001209191-18-013937-index.htm |
| 2018-02-26 | JOSHUA MAKOWER | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013935/0001209191-18-013935-index.htm |
| 2018-02-26 | PETER J BARRIS | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013928/0001209191-18-013928-index.htm |
| 2018-02-26 | Peter W. Sonsini | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013940/0001209191-18-013940-index.htm |
| 2018-02-26 | Ravi Viswanathan | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013942/0001209191-18-013942-index.htm |
| 2018-02-26 | SCOTT D SANDELL | 10% Share Holder | Sell | 1,460,209.00 | 0.50 | 731,272.67 | 0.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118013939/0001209191-18-013939-index.htm |
| 2018-02-27 | Brian L. Selby | VP, Finance | Sell | 161.00 | 0.53 | 85.33 | 1,114.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118015074/0001209191-18-015074-index.htm |
| 2020-09-21 | ROBERT E CONWAY | Director | Buy | 10,000.00 | 4.77 | 47,660.00 | 11,944.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919120051302/0001209191-20-051302-index.htm |
| 2018-04-03 | Thomas A Keuer | Chief Operating Officer | Sell | 482.00 | 0.50 | 241.72 | 13,153.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118023122/0001209191-18-023122-index.htm |
| 2018-02-28 | Thomas A Keuer | Chief Operating Officer | Sell | 410.00 | 0.72 | 294.38 | 13,635.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919118015077/0001209191-18-015077-index.htm |
| 2020-09-22 | ROBERT E CONWAY | Director | Buy | 3,056.00 | 4.66 | 14,240.65 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919120051890/0001209191-20-051890-index.htm |
| 2020-09-25 | ROBERT E CONWAY | Director | Buy | 5,000.00 | 4.28 | 21,399.50 | 20,000.00 | https://www.sec.gov/Archives/edgar/data/907654/000120919120052094/0001209191-20-052094-index.htm |
| 2018-02-26 | HEALTHCARE CAPITAL PARTNERS LP VENROCK | 10% Share Holder | Sell | 1,500,000.00 | 0.55 | 825,000.00 | 41,331.00 | https://www.sec.gov/Archives/edgar/data/907654/000145817718000001/0001458177-18-000001-index.htm |